Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
about
Melanoma-associated antigen synthesized in vitro for active specific immunotherapy.From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccineHuman monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.Advances in cancer vaccine development.Natural and induced human antibody response to cancer.Innovations and strategies for the development of anticancer vaccines.Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.Immunotherapy for melanoma.Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.Possibilities for active immunotherapy of human cancer.Recent Development in Carbohydrate Based Anti-cancer Vaccines.Immunotherapy for melanoma: current status and perspectives.Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies.Glycoimmunomics of human cancer: current concepts and future perspectives.Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.Epitope- and antigen-specific cancer vaccines.Role of gangliosides in active immunotherapy with melanoma vaccine.Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Toward automated oligosaccharide synthesis.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.Relevance for neurobiology and neurooncology of antigens of malignant gliomas as defined by monoclonal antibodies.Modulation of cancer patients' immune responses by anti-idiotypic antibodies.Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesionsCharacterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97.Melanoma, immune surveillance, and immunotherapy.Active specific immunotherapy against adenocarcinomas.Anti-idiotype and recombinant antigen in immunotherapy of colorectal cancer.Enhanced expression of unique gangliosides with GM2-determinant in human uterine cervical carcinoma-derived cell lines.Recognition of autoantigens by patients with melanoma.Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans.Immunotherapy of melanoma: current status and prospects for the future.Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.Tumor recognition by the cellular immune system: new aspects of tumor immunology.Update on active specific immunotherapy with melanoma vaccines.Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.Recent advances in the treatment of malignant melanoma with gene therapy.
P2860
Q33188234-9DE65F42-8458-4E0F-A44B-ABE11108F153Q33466255-58851E12-41FB-4CC0-A2D1-3E198E7931D2Q33557110-EC6C0B3E-C1E0-424C-B60D-FF0671F4D008Q33603404-C0898E84-C449-481C-928B-582B422062A0Q33931150-CA1FC1DC-5A43-443A-948E-2E436C020D94Q34182039-5CE7524D-40F9-4334-A7FD-AF9F02CC2167Q34504625-685D6424-218A-42A7-814A-7DE6E207C5C5Q34573035-433A2E10-D0F4-4035-A7B1-D00D7431D508Q35079733-03EF813C-DFB9-43BC-961B-049AD01AA453Q35326752-D0D64434-7C07-45CC-B171-B0CE61567BEEQ35854131-A77E7EF8-4AC4-4A2C-B60D-CAFF940DAF39Q36453216-0EAA45A3-0403-4822-97EE-36683302C3E8Q36501284-C657A4EC-5910-461E-B262-DBF8FC760A1EQ36768301-F4E3B64F-C0E8-49CF-BCB6-A4096C90ACFEQ36781607-132582D9-90C5-4D09-A865-13F6C761AA34Q36856279-45885212-F265-4A2C-A7C3-DE04E8A503B8Q36930069-2D0E9FD3-035D-4921-8F22-B61DAA0E4EE9Q36930077-65528DEC-171B-4DA3-8AA7-119C5DB687EDQ37053497-C48F6E6B-AF0F-4A0E-A0A2-D385E62371DDQ37608314-BBA2F82E-5A17-45D3-BA16-968BBD238170Q37952804-F42736A5-D806-4FBF-B666-3DBA25DCB196Q37962848-AFDA3DF0-C68C-4837-9CC6-81681095E65BQ37993590-BA497A33-0133-4214-A527-9D1D2BA3D71DQ38195895-7751B3C2-FA7B-4CF6-BA71-D28E2D3D27EAQ38246922-7F3A4FD2-C21C-4396-AADF-671E66C68FF1Q38569655-321802F9-7193-4CC6-9AFD-58370379D68EQ38784095-BD4ADC6A-8092-440A-82C0-05D41001AFF6Q40114484-65641D8F-76D4-4577-97FE-5DCAB603D86AQ40335389-4771BD18-3896-4304-83AA-E1CC0FA341C6Q40385527-53406B2F-0A2E-4D4C-8D77-86868A45DC04Q40517098-F68FAAB5-1DA1-4C5D-A5E2-8A292FEA3D20Q40714768-31469F8F-AC98-41AF-83D0-070FBCA1B426Q40844530-208CFDE5-D81D-4AD2-BB34-5A3131D78FB9Q40879087-D7A698A3-DC6C-439B-955A-3DF338EE1E39Q40899717-13896C14-C24B-4175-AAC3-5A6A4AE65DBCQ41194257-8E442749-D4FC-4995-BF60-0BB6DD285FFFQ41455911-18C7A6E0-E957-4C82-BAA5-11BE462B3A3DQ41589321-35BB9490-090F-4706-B6B8-5DC93F9BB15AQ41605409-9BFACABB-8158-41F2-B1A4-5D054077A12BQ41657233-7426C8A3-9ADC-40D6-8EF2-89D18ADD78B6
P2860
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
description
1987 nî lūn-bûn
@nan
1987 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@ast
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@en
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@nl
type
label
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@ast
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@en
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@nl
prefLabel
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@ast
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@en
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@nl
P2093
P2860
P356
P1476
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
@en
P2093
E J Natoli
E Stockert
H F Oettgen
M J Calves
P O Livingston
P2860
P304
P356
10.1073/PNAS.84.9.2911
P407
P577
1987-05-01T00:00:00Z